|By Marketwired .||
|March 4, 2014 02:00 AM EST||
MANCHESTER, UNITED KINGDOM -- (Marketwired) -- 03/04/14 -- Epistem Holdings Plc (LSE: EHP), Manchester, UK, the biotechnology and personalised medicine company, today announced that it has opened a US laboratory based in Baltimore, Maryland. The laboratory will support the expansion of Epistem's contract research division within the US. The US laboratory is currently offering histology and immunohistochemistry (IHC) services to a range of US clients, expanding upon the success of the GcLP and GLP compliant UK laboratory. The experienced and skilled technical team have already developed IHC protocols for a panel of over 150 antibodies which are available to clients worldwide.
Epistem Co-Founder and Director of the Contract Services Business, Dr Catherine Booth commented "Epistem's specialist contract research services provide valuable support to drug discovery and development pipelines. We already have strong relationships with both companies, academic and government groups on the East Coast along with a US Business team based in Boston and Baltimore. We are excited to now be providing services locally to support this growing US business".
Notes for editors
Epistem is a biotechnology and personalised medicine company commercialising its expertise in stem cells in the areas of epithelial (oncology, gastrointestinal and dermatological) and infectious diseases. Epistem develops innovative therapeutics, biomarkers and diagnostics (Genedrive®) alongside contract research services for drug development companies. The Group's core expertise is focused around the regulation of adult stem cells located in epithelial tissue including the gastrointestinal tract, skin, hair follicles, breast and prostate and utilizing novel, proprietary next generation molecular biology for use in personalised medicine. www.epistem.co.uk
Chief Executive Officer
+44 161 606 7258
+44 161 606 7258